Colin John Meyer - Jan 3, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Chief Innovation Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 04:01 PM
Previous filing
Jan 5, 2022
Next filing
Mar 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $0 +23.5K +45.22% $0.00 75.5K Jan 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right-to-buy) Award $0 +95.5K $0.00 95.5K Jan 3, 2023 Class A common stock 95.5K $36.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units, which vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date.
F2 The options vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date.